Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7

Jana C. Precht, Werner Schroth, Kathrin Klein, Hiltrud Brauch, Evgeny Krynetskiy, Matthias Schwab and Thomas E. Mürdter
Drug Metabolism and Disposition November 2013, 41 (11) 1906-1913; DOI: https://doi.org/10.1124/dmd.113.053405
Jana C. Precht
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Werner Schroth
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathrin Klein
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiltrud Brauch
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evgeny Krynetskiy
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Schwab
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas E. Mürdter
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 41 no. 11 1906-1913
DOI 
https://doi.org/10.1124/dmd.113.053405
PubMed 
23965986

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received June 20, 2013
  • Accepted August 21, 2013
  • Published online October 16, 2013.

Article Versions

  • Earlier version (August 21, 2013 - 07:07).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Jana C. Precht,
  2. Werner Schroth,
  3. Kathrin Klein,
  4. Hiltrud Brauch,
  5. Evgeny Krynetskiy,
  6. Matthias Schwab, and
  7. Thomas E. Mürdter
  1. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany (J.C.P., W.S., K.K., H.B., M.S., T.E.M.); Temple University School of Pharmacy, Philadelphia, Pennsylvania (E.K.); and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tübingen, Germany (M.S.)
  1. Address correspondence to:
    Thomas E. Mürdter, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Auerbachstr. 112, 70376 Stuttgart, Germany. E-mail: thomas.muerdter{at}ikp-stuttgart.de
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to March 2023

AbstractFullPdf
Aug 20170389
Sep 201714411
Oct 201702411
Nov 201733014
Dec 20170595
Jan 2018030311
Feb 201831748
Mar 2018219915
Apr 2018110610
May 2018310212
Jun 201805912
Jul 20181407
Aug 20181238
Sep 20180142
Oct 20183516
Nov 20180514
Dec 201887196
Jan 20195524
Feb 20194226
Mar 201945410
Apr 201941212
May 201921010
Jun 201918011
Jul 20192727
Aug 20193218
Oct 20193017
Nov 20193318
Dec 201937112
Jan 20201705
Feb 20201827
Mar 20203118
May 20202012
Jun 20204132
Jul 20201322
Aug 20201700
Sep 20208832
Oct 20201315
Nov 20201424
Dec 20204365
Jan 20212842
Feb 20211424
Mar 20212972
Apr 20212221
May 20213611
Jun 20211412
Jul 20211431
Aug 20211923
Sep 20211114
Oct 20211110
Nov 20212213
Dec 20212554
Jan 20221863
Feb 2022123104
Mar 20223631
Apr 20223934
May 20223521
Jun 20224110
Jul 20223419
Aug 20222142
Sep 20221310
Oct 20221932
Nov 20222231
Dec 20222215
Jan 20232011
Feb 20231614
Mar 20232210

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 41 (11)
Drug Metabolism and Disposition
Vol. 41, Issue 11
1 Nov 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Letrozole Metabolite Carbinol as Probe Drug for UGT2B7

Jana C. Precht, Werner Schroth, Kathrin Klein, Hiltrud Brauch, Evgeny Krynetskiy, Matthias Schwab and Thomas E. Mürdter
Drug Metabolism and Disposition November 1, 2013, 41 (11) 1906-1913; DOI: https://doi.org/10.1124/dmd.113.053405

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Letrozole Metabolite Carbinol as Probe Drug for UGT2B7

Jana C. Precht, Werner Schroth, Kathrin Klein, Hiltrud Brauch, Evgeny Krynetskiy, Matthias Schwab and Thomas E. Mürdter
Drug Metabolism and Disposition November 1, 2013, 41 (11) 1906-1913; DOI: https://doi.org/10.1124/dmd.113.053405
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A PBPK model for CBD in adults and children
  • Olanzapine Glucuronidation in Humanized Mice
  • rs2242480 Regulates the Expression of CYP3A4 and CYP3A5
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics